Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1821256 | 0.83 | KDM4E (0.35) | ALDH1A1TSHRKDM4EKMT2AMEN1 | |
| SCHEMBL1819414 | 0.81 | GAA (0.46) | ALDH1A1HSD17B10TSHRMAPTKMT2A | |
| SCHEMBL11777103 | 0.79 | ESR1 (0.36) | ALDH1A1HSD17B10TSHRMAPTTAS1R3 | |
| SCHEMBL11777747 | 0.76 | KDM4E (0.40) | ALDH1A1TSHRMAPTKDM4EPOLB | |
| SCHEMBL5942760 | 0.76 | KDM4E (0.44) | TSHRMAPTKDM4EMAPK1SMN1; SMN2 | |
| SCHEMBL2625747 | 0.72 | LMNA (0.47) | ALDH1A1HSD17B10TSHRNPSR1MAPT | |
| SCHEMBL8246277 | 0.69 | ALDH1A1 (0.55) | ALDH1A1HSD17B10TSHRMAPTKDM4E | |
| SCHEMBL10798128 | 0.68 | LMNA (0.39) | LMNA | |
| SCHEMBL2287151 | 0.68 | LMNA (0.47) | ALDH1A1HSD17B10TSHRMAPTKMT2A | |
| SCHEMBL12051647 | 0.67 | ALDH1A1 (0.49) | ALDH1A1HSD17B10TSHRNPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | AMGEN INC. | 2011-05-19 | — | — | US | claimed |
| EP-2300427-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2011-03-30 | — | — | EP | claimed |
| WO-2009137404-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-11-12 | — | — | WO | claimed |
| US-20110251172-A1 | PURINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. | 2011-10-13 | — | — | US | disclosed |
| US-20110207733-A1 | PYRIMIDINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. | 2011-08-25 | — | — | US | disclosed |
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | AMGEN INC. | 2011-05-19 | — | — | US | disclosed |
| EP-2312946-A1 | PYRIMIDINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | Merck Sharp & Dohme Corp. (US) | 2011-04-27 | — | — | EP | disclosed |
| EP-2312945-A1 | PURINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | Merck Sharp & Dohme Corp. (US) | 2011-04-27 | — | — | EP | disclosed |
| EP-2300427-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2010019393-A1 | PYRIMIDINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019392-A1 | PURINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2009137404-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | BACE1, BACE2, PSEN1 | ALDH1A1 2026/4885HSD17B10 2288/4885TSHR 4702/4885 |
| US-20110207733-A1 | PYRIMIDINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | TYMP, BACE1, TYMS | ALDH1A1 1945/4885HSD17B10 2959/4885TSHR 4696/4885 |
| US-20110251172-A1 | PURINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | BACE1, APP, PSEN1 | ALDH1A1 1553/4885HSD17B10 3434/4885TSHR 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.